The Longevity Genes in Founder Populations Project
ConditionExtreme Longevity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorAlbert Einstein College of Medicine
About this trial
We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes/mutations associated with healthier aging; to understand the biological functions of these genes/mutations; and to develop therapies to replicate these preservative genetic activities in individuals who do not have the genetic profile for longevity.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Ashkenazi Jewish, age 95+,
Offspring of person age 95+,
Offspring of parents who died age 70 or younger.
Disqualifiers
Non-Ashkenazis
Trial population
Ashkenazi Jews: Ages 95 and older, their offspring and control group with no family history of longevity.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
2,000 Participants
are grouped into 3 trial groupsGroup A: Probands
Group B: Offspring
Group C: Controls
Trial outcomes
This trial has no outcomes listed.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Albert Einstein College of Medicine
Lead sponsor
National Institute on Aging (NIA)
Collaborator
American Federation for Aging Research
Collaborator
Weill Medical College of Cornell University
Collaborator
Boston University
Collaborator
Regeneron Pharmaceuticals
Collaborator
Harvard Medical School (HMS and HSDM)
Collaborator
Stanford University
Collaborator
Tufts Medical Center
Collaborator
Columbia University
Collaborator
University of Minnesota
Collaborator
Rutgers Health
Collaborator
University of Rochester
Collaborator
Source ClinicalTrials.gov